Karen Smith - Sucampo Pharmaceuticals Director
Director
Dr. Karen L. Smith, M.D. Ph.D. M.B.A. LLM., was appointed as Director of the Comapny, with effective from July 15, 2017. Dr. Smith brings to Sucampo over 25 years of senior leadership and executive experience with both major pharmaceutical companies and startup biotechnology organizations. Her product development expertise spans various therapeutic areas and includes over 20 major drug and device approvals in North and Latin America, Asia, Europe and Australia. From 2011 to 2015, she was a Senior Vice President of Global Medical Affairs and Global Therapeutic Area Head for Allergan, a multispecialty health care company. From 2007 to 2010, Dr. Smith served initially as AstraZeneca Vice President of External Medical Relations, and later Vice President of Global Development. She held an array of management and medical roles at the BristolMyers Squibb Company in Australia, Canada and the United States. In 2001, she was also the Chief Executive Officer of Boron Molecular, a specialist fine chemicals manufacturing company. Dr. Smith previously served on the Women Advisory Board for Ironman Corporationrationration, Susan G. Komen and Girl Scouts and is currently Advisor to the CEO of Forward Pharma since 2017.
Age | 48 |
Tenure | 7 years |
Professional Marks | MBA |
Phone | 301 961-3400 |
Web | www.sucampo.com |
Sucampo Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0296 % which means that it generated a profit of $0.0296 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 14.16 %, meaning that it created $14.16 on every $100 dollars invested by stockholders. Sucampo Pharmaceuticals' management efficiency ratios could be used to measure how well Sucampo Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 293.54 M in liabilities with Debt to Equity (D/E) ratio of 740.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Sucampo Pharmaceuticals has a current ratio of 5.01, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Sucampo Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Sucampo Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sucampo Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sucampo to invest in growth at high rates of return. When we think about Sucampo Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | DIRECTOR Age | ||
Craig Ramsey | National CineMedia | 63 | |
Paula Madison | National CineMedia | 63 | |
Kurt Hall | National CineMedia | 58 | |
Joseph OLeary | Edgewell Personal Care | 62 | |
Mark Segall | National CineMedia | 55 | |
Scott Schneider | National CineMedia | 58 | |
Stephen Lanning | National CineMedia | 62 | |
Daniel Heinrich | Edgewell Personal Care | 64 | |
Phillip Mason | Lincoln Electric Holdings | 67 | |
Renana Teperberg | National CineMedia | 40 | |
Amanda Butler | Lincoln Electric Holdings | N/A | |
Lee Mitchell | National CineMedia | 81 | |
Rakesh Sachdev | Edgewell Personal Care | 64 | |
Kathryn Lincoln | Lincoln Electric Holdings | 63 | |
Andrew Glaze | National CineMedia | 39 | |
David Gunning | Lincoln Electric Holdings | 75 | |
Patrick Goris | Lincoln Electric Holdings | 46 | |
George Corbin | Edgewell Personal Care | 56 | |
William MacDonald | Lincoln Electric Holdings | 71 | |
Gary Waring | Edgewell Personal Care | 61 | |
James Johnson | Edgewell Personal Care | 68 |
Management Performance
Return On Equity | 14.16 | |||
Return On Asset | 0.0296 |
Sucampo Pharmaceuticals Leadership Team
Elected by the shareholders, the Sucampo Pharmaceuticals' board of directors comprises two types of representatives: Sucampo Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sucampo. The board's role is to monitor Sucampo Pharmaceuticals' management team and ensure that shareholders' interests are well served. Sucampo Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sucampo Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Barbara Munder, Independent Director | ||
Peter Pfreundschuh, CFO, Principal Financial Officer | ||
Matthew Donley, Executive VP of HR | ||
Max Donley, Executive Vice President of Human Resources | ||
Peter Kiener, Chief Scientific Officer | ||
Matthias Alder, Executive Vice President - Business Development & Licensing | ||
Daniel Getman, Independent Chairman of the Board | ||
Peter Greenleaf, Chairman and CEO | ||
Silvia Taylor, Senior Vice President - Investor Relations, Public Relations and Corporate Communications | ||
Peter Lichtlen, Chief Medical Officer | ||
Stanley Miele, Sr. VP of Sales and Marketing and President of Sucampo Pharma Americas LLC | ||
Andrew Smith, Principal Accounting Officer | ||
Timothy Walbert, Director | ||
John Johnson, Director | ||
Paul Edick, Director | ||
Alex Driggs, Acting General Counsel, Corporate Secretary | ||
Karen Smith, Director | ||
Robert Spiegel, Director | ||
Maureen OConnell, Independent Director | ||
Thomas Knapp, Executive Vice President Chief Legal Officer and Corporate Secretary |
Sucampo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sucampo Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 14.16 | |||
Return On Asset | 0.0296 | |||
Profit Margin | 7.80 % | |||
Operating Margin | 30.77 % | |||
Current Valuation | 1.05 B | |||
Shares Outstanding | 47.09 M | |||
Shares Owned By Insiders | 35.13 % | |||
Shares Owned By Institutions | 82.48 % | |||
Number Of Shares Shorted | 4.59 M | |||
Price To Earning | (2.77) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Sucampo Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Sucampo Pharmaceuticals' short interest history, or implied volatility extrapolated from Sucampo Pharmaceuticals options trading.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Other Consideration for investing in Sucampo Stock
If you are still planning to invest in Sucampo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sucampo Pharmaceuticals' history and understand the potential risks before investing.
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data |